摘要
目的通过观察肝组织病理学指标,评价IFN-!联合安珐特治疗慢性乙型肝炎肝纤维化的临床疗效。方法住院治疗的35例慢性乙肝患者,经肝穿证实病理纤维化程度均在S2以上,随机分组。治疗组22例,用IFN-!1MU,皮下注射,每日一次,12周后改隔日一次,同时口服安珐特,2粒/次,每日三次,总疗程36周。对照组13例,服用一般护肝药物,疗程36周。治疗后再行肝穿术并做肝组织病理分级分期诊断。结果治疗组治疗后肝组织纤维化明显下降,与治疗前有显著性差异(P<0.05),并与治疗后对照组亦有显著性差异(P<0.05)。结论IFN-!联合安珐特是抗肝纤维化的较好配伍治疗。
Objective To evaluate the efficacy of interferon gamma （IFN-γ） and An.Fa.Te in the treatment of chronic hepatitis B （CHB）. Method Thirty-five CHB patients with liver fibrosis of greater than S2 were divided randomly into two groups. Twenty-two patients were treated with IFN-γ and An.Fa.Te for 36 weeks and patients in the control group were treated with liver-care medicine. Liver biopsy was performed before and after therapy. Biopsies were diagnosed according to the pathological grading and stage. Result The grading and the stage of liver fibrosis were significantly lower in patients after IFN-γ and An.Fa.Te treatment （P〈0.05）. The grading was also lower than patients in the control group（P〈0.05）. Conclusion Combination of IFN-γ and An.Fa.Te may be used to reduce fibrosis in the patients with CHB.
出处
《热带医学杂志》
CAS
2006年第4期412-413,418,共3页
Journal of Tropical Medicine
